パチスロ今打つなら Release

Top
パチスロ今打つなら

Latest パチスロ今打つなら

May 11, 2023: Notice of Relocation of Head Office
May 11, 2023: Notice of Extraordinary Income as Result of Absorption-Type Merger
April 27, 2023: パチスロ今打つなら website has been relaunched today.
April 3, 2023: Notice of Absorption Type Merger of Wholly Owned Subsidiary パチスロ今打つなら Pharmaceutical Co., Ltd and Change of Trade Name
March 6, 2023: パチスロ今打つなら and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries
February 6, 2023: Summary of Consolidated Financial パチスロ今打つなら(For the third quarter ended December 31, 2022) [Japanese GAAP]
February 6, 2023: Third Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2023 (Feb 6, 2023) - Supplementary Information
November 9, 2022: パチスロ今打つなら and SUSMED conclude Collaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
November 9, 2022: Second Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information
November 9, 2022: Summary of Consolidated Financial パチスロ今打つなら(For the second quarter ended September 30, 2022) [Japanese Standard]
August 2, 2022: Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc.
August 2, 2022: First Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
August 2, 2022: Summary of Consolidated Financial パチスロ今打つなら(For the first quarter ended June 30, 2022) [Japanese Standard]
June 17, 2022: パチスロ今打つなら Signs Joint Development and License Agreement for Genetically modified Adipocyte, Treatment Agent for Fabry Disease
May 17, 2022: Notice of Resumption of Operation at Nishinihon Delivery Center
May 11, 2022: Notice of Reduction of Capital Reserve
May 11, 2022: Absorption Type Merger (Simplified Merger and Short-Form Merger) of Wholly Owned Subsidiary　パチスロ今打つなら Pharmaceutical Co., Ltd., Change of Trade Name and Partial Amendment to Articles of Incorporation
May 11, 2022: Consolidated Financial パチスロ今打つなら for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information
May 11, 2022: Summary of Consolidated Financial パチスロ今打つなら(For the fiscal year ended March 31, 2022) [Japanese Standard]
April 26, 2022: Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
April 20, 2022: NHI Drug Price Listing and パチスロ今打つなら of a selective P2X3 receptor antagonist for the treatment of cough "Lyfnua® Tablet 45 mg"
March 30, 2022: パチスロ今打つなら and Lumen Bioscience Reach Collaboration Research Agreement
March 17, 2022: パチスロ今打つなら and Nanjing Neiwa Faith Signed License Agreement for Lascufloxacin in China
February 24, 2022: Construction of the Takaoka New Plant by a Subsidiary Company
February 4, 2022: Summary of Consolidated Financial パチスロ今打つなら (For the Third Quarter Ended December 31, 2021) [Japanese Standard]
February 4, 2022: Third Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2022 - Supplementary Information
February 4, 2022: Notice of Merger Preparations at Consolidated Subsidiary, パチスロ今打つなら Pharmaceutical Co., Ltd.
January 20, 2022: MSD K.K. receives manufacturing and marketing approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough
January 17, 2022: パチスロ今打つなら-promotion agreement in Japan for oral COVID-19 treatment LAGEVRIO Capsules 200 mg
December 27, 2021: パチスロ今打つなら Signed Memorandum of Understanding on Co-Promotion of "Lagevrio Capsule 200mg" for COVID-19 Treatment
November 30, 2021: Launch of "Compact Real Time PCR System GeneSoC® mini"
November 8, 2021: Summary of Consolidated Financial パチスロ今打つなら (For the Second Quarter Ended September 30, 2021) [Japanese Standard]
November 8, 2021: Second Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2022 - Supplementary Information
August 3, 2021: Summary of Consolidated Financial パチスロ今打つなら (August 3,2021) [Japanese Standard]
August 3, 2021: First Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2022 - Supplementary Information
May 11, 2021: Summary of Consolidated Financial パチスロ今打つなら　(For the fiscal year ended March 31, 2021) [Japanese Standard]
May 11, 2021: Consolidated Financial パチスロ今打つなら for the Fiscal Year Ended March 31, 2021 - Supplementary information
May 7, 2021: The Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2021
April 26, 2021: MSD and パチスロ今打つなら Conclude Distribution Agreement of Gefapixant Citrate, a Treatment for Chronic Cough, in Japan
April 21, 2021: Launch of the Interstitial cystitis "Zymso® Intravesical Solution 50%"
March 31, 2021: パチスロ今打つなら and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
February 18, 2021: NHI Drug Price Listing and パチスロ今打つなら of injectable New Quinolone Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
February 4, 2021: Summary of Consolidated Financial パチスロ今打つなら (For the Second Quarter Ended December 31, 2020) [Japanese Standard]
February 4, 2021: Third Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2021 - Supplementary Information
January 29, 2021: パチスロ今打つなら of four research reagents for Microfluidic Real-Time PCR System GeneSoC®
January 22, 2021: パチスロ今打つなら Pharmaceutical Receives Marketing Approval for the Interstitial cystitis "Zymso® Intravesical Solution 50%"
November 27, 2020: パチスロ今打つなら Pharmaceutical Receives Marketing Approval for injectable New Quinolone Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
November 5, 2020: Summary of Consolidated Financial パチスロ今打つなら (For the Second Quarter Ended September 30, 2020) [Japanese Standard]
November 5, 2020: Second Quarter Consolidated Financial パチスロ今打つなら for the Fiscal Year Ending March 31, 2021 - Supplementary Information
November 5, 2020: The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2021